Hypnosis in Internal Medecine

NCT04698824 | Unknown

• 1 other identifier: 2020-A03469-30
• Study Type: observational
• Target: 70
• Locations: 0 countries
• Sites: N/A

Brief Summary

Description of the short and long-term impact of hypnosis sessions for patient having benefited from at least one hypnosis session in internal medicine at the french hospital "Groupe Hospitalier Mutualiste de Grenoble", with the help of a qualitative survey made by phone.

Conditions

Hypnosis; Autoimmune Diseases; Medically Unexplained Symptoms

Keywords

internal medicine; survey; qualitative; impact of hypnosis

Outcome Measures

Primary Outcomes (1)

• Description of the short and long-term impact of hypnosis sessions thanks to a qualitative phone survey

  Improvement in symptoms and quality of life, assessed thanks to a qualitative phone survey by 5-levels Likert scales

  Assessed only once. Phone call will be performed between march 2021 and June 2021

Secondary Outcomes (2)

• Assessment of the reasons for patient satisfaction / dissatisfaction

  Assessed only once. Phone call will be performed between march 2021 and June 2021

• Description of the characteristics of these patients and of the hypnosis sessions

  At inclusion

Interventions

Hypnosis session PROCEDURE

At least one session of hypnosis in the internal medicine unit at the hospital "Groupe Hospitalier Mutualiste de Grenoble"

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All consecutive patients who had at least one hypnosis session in internal medicine at the hospital "Groupe Hospitalier Mutualiste de Grenoble" between 08/28/2015 (date of the very first hypnosis consultation in internal medicine) and 03/17/2020 (date of confinement due to Covid19 in France)

You may qualify if:

• All consecutive patients who had at least one hypnosis session in internal medicine at the hospital "Groupe Hospitalier Mutualiste de Grenoble" between 08/28/2015 (date of the very first hypnosis consultation in internal medicine) and 03/17/2020 (date of confinement due to Covid19 in France)

You may not qualify if:

• Patient who had a hypnosis session, but who is not followed for a pathology in internal medicine or in internal medicine with a pneumological orientation

Sponsors & Collaborators

• University Hospital, Grenoble: lead
• Groupe Hospitalier Mutualiste de Grenoble: collaborator

Related Publications (4)

• Lugosi M, Sacre K, Lidove O, Chauveheid MP, Brihaye B, Laissy JP, Chauchard M, Papo T. [Long-term follow-up of a French cohort of retroperitoneal fibrosis]. Rev Med Interne. 2013 Oct;34(10):591-9. doi: 10.1016/j.revmed.2013.02.002. Epub 2013 Mar 14. French.

  PMID: 23498668 BACKGROUND

• Lugosi M, Alberti C, Zahar JR, Garrouste M, Lemiale V, Descorps-Desclere A, Ricard JD, Goldgran-Toledano D, Cohen Y, Schwebel C, Vesin A, Timsit JF, Azoulay E. Aspergillus in the lower respiratory tract of immunocompetent critically ill patients. J Infect. 2014 Sep;69(3):284-92. doi: 10.1016/j.jinf.2014.04.010. Epub 2014 Jun 9.

  PMID: 24924557 BACKGROUND

• Tolsma V, Schwebel C, Azoulay E, Darmon M, Souweine B, Vesin A, Goldgran-Toledano D, Lugosi M, Jamali S, Cheval C, Adrie C, Kallel H, Descorps-Declere A, Garrouste-Orgeas M, Bouadma L, Timsit JF. Sepsis severe or septic shock: outcome according to immune status and immunodeficiency profile. Chest. 2014 Nov;146(5):1205-1213. doi: 10.1378/chest.13-2618.

  PMID: 25033349 BACKGROUND

• Gunther SC, Schwebel C, Hamidfar-Roy R, Bonadona A, Lugosi M, Ara-Somohano C, Minet C, Potton L, Cartier JC, Vesin A, Chautemps M, Styfalova L, Ruckly S, Timsit JF. Complications of intravascular catheters in ICU: definitions, incidence and severity. A randomized controlled trial comparing usual transparent dressings versus new-generation dressings (the ADVANCED study). Intensive Care Med. 2016 Nov;42(11):1753-1765. doi: 10.1007/s00134-016-4582-2. Epub 2016 Oct 12.

  PMID: 27734108 BACKGROUND

MeSH Terms

Conditions

Autoimmune Diseases; Medically Unexplained Symptoms

Condition Hierarchy (Ancestors)

Immune System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Maxime LUGOSI, PhD

  CHU Grenoble Alpes

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Maxime LUGOSI, PhD

CONTACT

04 76 76 37 07; mlugosi@chu-grenoble.fr

Mélanie ARNAUD

CONTACT

marnaud3@chu-grenoble.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 4, 2021
• First Posted: January 7, 2021
• Study Start: June 1, 2021
• Primary Completion: July 1, 2021
• Study Completion: October 1, 2021
• Last Updated: May 5, 2021

Record last verified: 2021-05

Data Sharing

• IPD Sharing: Will not share